# 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

> **NCT04464200** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma
- Primary Mediastinal Large B Cell Lymphoma
- Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Indolent Non-Hodgkin Lymphoma
- Marginal Zone Lymphoma
- Waldenstrom Macroglobulinemia
- Burkitt's Lymphoma
- Primary CNS Lymphoma

## Interventions

- **DRUG:** 19(T2)28z1xx CAR T cells

## Key facts

- **NCT ID:** NCT04464200
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-06
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04464200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04464200, "19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04464200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*